About
Nyxoah is a medical device company focused on the development and commercialization of hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea (OSA). The company has developed a battery-free, leadless, minimally invasive neurostimulator capable of delivering bilateral hypoglossal nerve stimulation for patients with moderate to severe OSA who have failed at conventional positive airway pressure therapy. Nyxoahs therapy consists of a tiny neurostimulator that is implanted in the chin area in a minimally invasive surgery. The system, which is powered by a miniature external battery, is placed under the chin and stimulates the tongue nerve. In March 2019, Nyxoah received CE marking for its novel hypoglossal nerve stimulation therapy for treatment of obstructive sleep apnea. In January 2021, Nyxoah received CE mark magnetic resonance imaging (MRI) conditional labeling for the current Genio neurostimulation-based OSA therapy for treatment of obstructive sleep apnea.
Funding history · 7 rounds · $270.7M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Nyxoah receive CE marking for its hypoglossal nerve stimulation therapy for obstructive sleep apnea?
- Nyxoah received CE marking for its novel hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea in March 2019.
- What significant regulatory approval did Nyxoah receive in January 2021?
- In January 2021, Nyxoah received CE mark magnetic resonance imaging (MRI) conditional labeling for its Genio neurostimulation-based OSA therapy.
- When did Nyxoah go public on Euronext?
- Nyxoah became public on Euronext in September 2020.
- When did Nyxoah go public on NASDAQ?
- Nyxoah became public on NASDAQ in July 2021.
- Which investors participated in Nyxoah's Series B funding round in November 2018?
- In November 2018, Cochlear Limited invested in Nyxoah's Series B funding round.
- Which companies invested in Nyxoah's undisclosed funding round in February 2020?
- In February 2020, Cochlear Limited and ResMed invested in Nyxoah's undisclosed funding round.
- What was the amount of Nyxoah's latest PIPE funding round and when did it occur?
- Nyxoah's latest PIPE funding round occurred in October 2024 and raised $27,000,000.
- When did Nyxoah secure FDA clearance for its Genio System to treat sleep apnea?
- Nyxoah secured FDA clearance for its Genio System to treat sleep apnea in August 2025.
- What strategic partnership did Nyxoah announce in September 2023?
- In September 2023, Nyxoah announced a partnership with ResMed in Germany.
- What was a key development for Nyxoah in the Middle East in February 2026?
- In February 2026, Nyxoah announced the signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to improve OSA therapy management and accelerate access to Genio in the Middle East.